StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Morgan Stanley

BUYDr. Lal Path Labs Ltd.

byMorgan StanleyHorizon: NA (inferred 1 year)27 Jul 2026via NDTV Profit

Entry₹1,827.2Inferred
Target₹1,960
Total upside +7.27% (call closed)
Stop lossNot given
Exit₹1,96010 Aug 2026, 12:08 pm
Target hit+7.27%0.00%upside left
Follow Morgan Stanley for new calls(83% target hit, 12 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 1 active Long-term call on LALPATHLABSee 72 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 10 Aug 2026
11 supporting2 neutral0 opposing
Supports the BUY call (11)

Metropolis Healthcare: చిన్న పట్టణాల్లో దూసుకుపోతోంది.. లాభాల్లో **26%** వృద్ధి!

NewsGoogle News·6 Aug · 3d ago

(opens in new tab)

Metropolis Healthcare शेअरमध्ये तेजी! टियर-II/III शहरांमधील विस्ताराने नफा **26%** ने वाढला

NewsGoogle News·6 Aug · 3d ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·30 Jul · 1w ago

Dr Lal Path Labs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?

NewsEt-Markets·27 Jul · 2w ago

(opens in new tab)

Dr. Lal PathLabs reported Q1 FY27 results with revenue up 19.1% to Rs 798 Cr. EBITDA increased 28.7% to Rs 247 Cr. PAT was Rs 170 Cr. The company also announced an interim dividend of 50% (Rs 5/share)

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

The Board of Directors approved un-audited financial results for Q1 FY27, declared an interim dividend of INR 5 per share, and approved the grant of stock options. Additionally, the company approved a

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.